References

Methylation sequencing features
a lower limit of detection
(LoD) and a signal independent
from clonal hematopoiesis of indeterminate potential (CHIP) variants/biological noise.¹

Methylation-based detection identifies and quantifies tumor signals in early- and late-stage cancers with as low as 0.001% circulating tumor fraction (TF).¹

Methylation-based tumor fraction has superior sensitivity, enabling identification of tumor signal in 15%-50% more cancer patients.¹

Methylation sequencing dramatically improves sensitivity in cancer monitoring vs genomic signals alone.¹